RxDoctor Payments Data

Carmen Aguirre, PA

Physician Assistant · Colorado Springs, CONPI 1669538161

Payments from drug & device makers

$1,873in general payments, 2019–2025

Across 17 payments — averaging $110.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$483
  • Novo Nordisk$460
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$346
  • Biohaven Pharmaceutical Holding Company Ltd.$196
  • Heartflow, Inc.$167
  • Novartis$117
  • plus $105 from 1 others

What the payments were for

  • Food & beverage$1,873100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,873 in reported general payments places this provider in the 85th percentile of 2,849 physician assistant providers in Colorado.

See all physician assistant providers in Colorado

Medicare billing

Part B allowed, 2024
$45,260
Medicare patients
180
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$85,437
JardianceEmpagliflozin27$41,413
TrulicityDulaglutide26$34,483
EliquisApixaban22$24,849
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$4,806
Levemir FlexpenInsulin Detemir12$3,371
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,363
Boostrix TdapDiphth,pertuss(Acell),tet Vac29$2,032
Levothyroxine Sodium218$1,821
Losartan Potassium208$1,388
Omeprazole101$1,274
Atorvastatin Calcium173$1,261
Albuterol Sulfate HfaAlbuterol Sulfate40$1,216
Duloxetine Hcl36$1,122
Ibandronate Sodium20$1,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$460$85,43777 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,849 physician assistant providers in Colorado.

Other physician assistant in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →